A Study of TAK-881 and HyQvia in Healthy Adults
Phase 1
Completed
NCT06895967
| Condition | Healthy Volunteers |
|---|
| Phase | Phase 1 |
|---|
| Sponsor | Takeda |
|---|
| Status | Completed |
|---|
| Enrollment | 30 participants |
|---|
| Interventions | TAK-881, HyQvia, SC Investigational Needle Sets, SC Investigational Needle Sets |
|---|
| Start date | Mar 24, 2025 |
|---|
| Completion date | Jul 24, 2025 |
|---|
| Results posted | May 11, 2026 |
|---|
Summary
The main aim of this study is to understand how the body absorbs, processes, and removes (known as pharmacokinetics or PK) TAK-881 and HyQvia, after they are given as a single injection under the skin in healthy adults. Study participants will receive a single dose of TAK-881 or HyQvia on Day 1. During the study, participants will need to stay at the clinic for 8 days followed by 8 ambulatory follow up visits till Day 85.
Baseline-corrected Area Under the Concentration-time Curve (AUC) From Day 1 to Day 29 (AUC Day 1-29) Based on Serum Total Immunoglobulin G (IgG) Levels
Day 1 up to Day 29 · gram*hour per liter (g*h/L)
| TAK-881 1.0 g/kg | 2993 ± 13.6 gram*hour per liter (g*h/L) |
|---|
| HyQvia 1.0 g/kg | 3190 ± 25.4 gram*hour per liter (g*h/L) |
|---|
| Geometric mean ratio | 93.82 (95% CI 80.38–109.52) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.